CAPR241220P10000
- 0.10
- 0.000.00%
Capricor Therapeutics Newsroom
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Wins Key EU Designations for the Lead Asset
Capricor Therapeutics Granted Orphan Drug And ATMP Status For Deramiocel By EMA
Express News | Capricor Therapeutics Inc - Expects to Complete Bla Submission by End of 2024
Express News | Capricor Therapeutics Granted Orphan Drug and Atmp Status for Deramiocel by European Medicines Agency
Capricor Therapeutics Analyst Ratings
Capricor Therapeutics Initiated With a Buy at JonesResearch
Express News | Capricor Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $40
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Capricor Therapeutics | 10-Q: Q3 2024 Earnings Report
Decoding 12 Analyst Evaluations For Capricor Therapeutics
Cantor Fitzgerald Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Raises Target Price to $30
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $43
Capricor Therapeutics Price Target Raised to $30 From $25 at Cantor Fitzgerald
Piper Sandler Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $35
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Capricor Therapeutics: Strategic Positioning and Financial Stability Drive Buy Rating
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript Summary
Capricor Therapeutics Advances With Strategic Expansions
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript